Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.53 |
| ▸ | BCHE | P06276 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20118989 | 0.82 | LMNA (0.53) | ACHEBCHEALDH1A1LMNAFAAH | |
| SCHEMBL20173765 | 0.79 | ACHE (0.45) | ACHEBCHE | |
| SCHEMBL20178579 | 0.78 | ACHE (0.44) | ACHEBCHESMN1; SMN2 | |
| SCHEMBL29358693 | 0.78 | ACHE (0.71) | ACHEBCHEKDM4EALDH1A1LMNA | |
| SCHEMBL5933261 | 0.78 | ACHE (0.71) | ACHEBCHEKDM4EALDH1A1LMNA | |
| SCHEMBL25820322 | 0.77 | ACHE (0.54) | ACHEBCHEKDM4EALDH1A1LMNA | |
| SCHEMBL20173760 | 0.76 | KAT6A (0.54) | ALDH1A1LMNASMN1; SMN2 | |
| 3-Isopropylphenyl Dimethylcarbamate SCHEMBL26378341 | 0.75 | ACHE (0.77) | ACHEBCHELMNAFAAH | |
| SCHEMBL28119215 | 0.74 | ACHE (0.51) | ACHEBCHEKDM4EALDH1A1LMNA | |
| SCHEMBL25847360 | 0.74 | BCHE (0.51) | ACHEBCHEALDH1A1SMN1; SMN2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | ACHE 4086/4885BCHE 1491/4885KDM4E 4005/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | ACHE 4086/4885BCHE 1491/4885KDM4E 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.